All In Biotech

Drug Trial Radar · NCT05120830

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

37

Actual

Start

Dec 10, 2021

Primary completion

Apr 4, 2024

Study completion May 31, 2027

Sponsor

Lead sponsor
Intellia TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Conditions

  • Hereditary Angioedema

Interventions

  • Biological NTLA-2002Biological

    CRISPR/Cas9 gene editing system delivered by LNP for IV administration

  • Normal Saline IV AdministrationOther

    The administration of IV normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of NTLA-2002 as determined by adverse events (AEs) and dose limiting toxicities (DLTs)Time frame: From NTLA-2002 infusion up to week 104 post-infusion
  2. Number of HAE attacks per month (Weeks 1-16)Time frame: From study drug infusion up to week 16 post-infusion

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Campbelltown, Australia

  • Clinical Trial Site

    Grenoble, France

  • Clinical Trial Site

    Lille, France

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Berlin, Germany

  • Clinical Trial Site

    Frankfurt, Germany

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    Auckland, New Zealand

  • Clinical Trial Site

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.